BEIGENE, LTD.

(BGNE)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 08-08-2022
202.24 USD   +4.00%
08/08BEIGENE, LTD. : Nomura ontvangt een koopadvies
MM
08/08BEIGENE, LTD. : Nomura handhaaft koopadvies
MM
04/08BeiGene Q2 nettoverlies per ADS wordt groter bij stijgende inkomsten
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société BEIGENE, LTD.
08/08BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
04/08BEIGENE : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
04/08BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
04/08BeiGene Reports Second Quarter 2022 Financial Results
BU
20/07BEIGENE, LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
15/07BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
15/07BEIGENE : Provides Regulatory Update on the U.S. Biologics License Application (BLA) for P..
PU
14/07BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for ..
BU
13/07BeiGene Appoints Chan Lee as General Counsel
BU
06/07BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Nov..
BU
30/06BEIGENE : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tis..
PU
30/06BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
30/06BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
BU
23/06BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for ..
PU
22/06BEIGENE, LTD. : Change in Directors or Principal Officers, Submission of Matters to a Vote..
AQ
21/06BeiGene Announces Acceptance of Supplemental Biologics License Application in China for..
BU
14/06BEIGENE : Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at ..
PU
14/06BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
13/06BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
BU
13/06BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatmen..
BU
10/06BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at..
BU
10/06China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
BU
08/06BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
BU
27/05BEIGENE : Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and G..
PU
27/05BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
26/05BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and ..
BU
17/05BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
BU
12/05BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
09/05BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/05BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
05/05BeiGene Reports First Quarter 2022 Financial Results
BU
04/05BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for P..
BU
29/04BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton Wes..
BU
29/04BEIGENE : Financial Information - Form 8-K
PU
28/04BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
28/04BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, ..
BU
27/04BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual..
BU
27/04Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Che..
BU
26/04BeiGene Introduces Global Environmental, Social, and Governance Strategy
BU
25/04Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
AQ
21/04BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Can..
BU
20/04BEIGENE : China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamo..
PU
20/04BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
19/04BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tis..
BU
15/04China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell..
BU
12/04BEIGENE : Announces European Medicines Agency Acceptance of Marketing Authorization Applic..
PU
12/04BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/04IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Ver..
BU
08/04BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors ..
BU
06/04BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Appli..
BU
25/03BEIGENE : Current Report (Form 8-K)
PU
25/03BEIGENE, LTD. : Changes in Registrant's Certifying Accountant, Other Events, Financial Sta..
AQ
17/03BEIGENE : China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-Hi..
PU
17/03BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
15/03BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA..
BU
11/03China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or M..
BU
03/03BEIGENE, LTD. : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
03/03BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Re..
BU
03/03BEIGENE : An announcement has just been published by the issuer in the Chinese section of ..
PU
01/03BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference
BU
28/02BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
25/02BEIGENE : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
25/02BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
25/02BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
BU
22/02BEIGENE : Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zan..
PU
22/02BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
22/02BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA..
BU
22/02BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (za..
BU
17/02BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of A..
BU
16/02BEIGENE, LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/02BEIGENE : Initial Statement of Beneficial Ownership (Form 3)
PU
08/02BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
BU
02/02BEIGENE : Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors ..
PU
02/02BEIGENE, LTD. : Change in Directors or Principal Officers, Other Events, Financial Stateme..
AQ
01/02Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
BU
1  2  3  4  5  6  7  8Volgende
Volgende evenement op BEIGENE, LTD.